Ipamorelin
NNC 26-0161
- Peptide length
- 5 amino acids
Modified pentapeptide
Open the sources to check how the studies were done and what they can support.
A synthetic growth-hormone secretagogue whose original pharmacology was characterized in cells and animals; human development has also investigated gastrointestinal recovery.
- Family
- Ghrelin-receptor agonist
- Research target
- Ghrelin receptor (GHSR)
- Molecular form
- Modified pentapeptide
- Formula reported by the source
- C38H49N9O5
What to know about the research
The early selectivity work used cells and animals. In the later postoperative-ileus trial, ipamorelin did not significantly outperform placebo on the key or secondary efficacy analyses.
Check the exact compound
Non-natural residues and terminal amidation are part of the identity. Do not infer identity from an unmodified five-letter sequence.
What supports this entry?
3 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
A synthetic growth-hormone secretagogue whose original pharmacology was characterized in cells and animals; human development has also investigated gastrointestinal recovery.
Abstract: Patients, Intervention, Main outcome measures, Results and Conclusions
Abstract: opening pentapeptide structure and rat-cell, rat and swine experiments
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the evidence limitationSource checked
The early selectivity work used cells and animals. In the later postoperative-ileus trial, ipamorelin did not significantly outperform placebo on the key or secondary efficacy analyses.
Abstract: Patients, Intervention, Main outcome measures, Results and Conclusions
Abstract: opening pentapeptide structure and rat-cell, rat and swine experiments
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the identity statementSource checked
Non-natural residues and terminal amidation are part of the identity. Do not infer identity from an unmodified five-letter sequence.
Abstract: opening pentapeptide structure and rat-cell, rat and swine experiments
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Inside the selected studies
Phase II randomized, double-blind, placebo-controlled trial
Intravenous ipamorelin
- Who or what was studied
- Adults undergoing bowel resection
- Sample size
- 117
- Compared with
- Placebo
- Duration
- Up to seven postoperative days or discharge
- Time to tolerating a solid meal: no significant group difference (p=0.15).
- No significant difference in key or secondary efficacy analyses.
- Selected study only; source mapping is not independent study-quality appraisal.
- 117 enrolled; 114 formed the safety and modified intent-to-treat populations. Small proof-of-concept study.